Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 105 clinical trials
Peri-operative SLOG for Localized Pancreatic Cancer

To evaluate the efficacy of neoadjuvant chemotherapy SLOG in localized pancreatic cancer To evaluate the safety profile in patients with pancreatic cancer who receive neoadjuvant SLOG To collect tumor tissue and peripheral blood samples from the patients for a comprehensive biomarker evaluation

oxaliplatin
platelet count
resectable pancreatic cancer
gemcitabine
cancer chemotherapy
  • 0 views
  • 26 Sep, 2021
  • 3 locations
A Multicentric Phase 1/2 Trial to Evaluate the Safety and Efficacy of SOT102 as Monotherapy and in Combination With Standard of Care Treatment in Patients With Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01)

This trial will assess the MTD and RP2D of SOT102 administered as monotherapy (Part A) and in combination with first-line SoC treatment (mFOLFOX6 with nivolumab and nab-paclitaxel/ gemcitabine; Part B) and efficacy of SOT102 administered as monotherapy (Part C) and in combination with first-line SoC treatment (Part D) in patients …

  • 0 views
  • 18 Sep, 2022
  • 1 location
Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers (FBI-TRAC)

This study is to evaluate the response rate and toxicity profile of infusional 5 fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) in first-line treatment of advanced biliary tract cancers and also to assess progression free survival and overall survival of FOLFIRINOX in first line treatment of advanced biliary tract cancers

oxaliplatin
platelet count
biliary cancer
fluorouracil
renal function
  • 5 views
  • 25 Feb, 2022
  • 1 location
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients

The aim of this study is to evaluate the safety and effectiveness of Fruquintinib combined with Albumin Paclitaxel and Gemcitabine on pancreatic cancer patients with liver metastases. Plan to enrollment 30 patients.

gemcitabine
metastatic pancreatic cancer
neutrophil count
paclitaxel
measurable disease
  • 0 views
  • 25 Mar, 2022
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001)

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

direct bilirubin
sarcoma
gastric carcinoma
ovarian carcinoma
ovarian epithelial carcinoma
  • 33 views
  • 25 Jul, 2022
  • 25 locations
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies. These advances have resulted in a myriad of benefits for patients including decreased morbidity, mortality, as well as increased longevity and …

metastasis
cancer
carcinoma
  • 0 views
  • 12 May, 2022
  • 1 location
Cholesterol Disruption in Combination With FOLFIRINOX in Patients With Metastatic Pancreatic Adenocarcinoma

Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression. All cells require cholesterol, but cancer cells have much higher needs to sustain growth, division and metastasis. The availability of new cholesterol-lowering drugs developed to protect patients from heart diseases has resulted …

adenocarcinoma
pancreatic adenocarcinoma
metastasis
breast ductal carcinoma
cancer chemotherapy
  • 0 views
  • 27 Nov, 2021
  • 1 location
Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

This phase I trial is designed as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have a tumor lesion which is …

cancer chemotherapy
cytotoxic t-lymphocyte antigen 4
serum pregnancy test
immunologic adjuvant
fluorouracil
  • 0 views
  • 10 Jul, 2022
  • 2 locations
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors

This trial is an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with CLDN18.2-positive tumors. The trial design consists of three parts: Part 1A is a dose escalation of BNT141 as monotherapy in patients with advanced unresectable or metastatic …

adenocarcinoma
pancreatic adenocarcinoma
immunohistochemistry
metastatic gastric cancer
gemcitabine
  • 0 views
  • 20 Sep, 2022
  • 6 locations
LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors

platelet count
tubal ligation
gemcitabine
zoledronic acid
neutrophil count
  • 2 views
  • 09 Dec, 2021
  • 10 locations